Moberg strikes Africa deal
This article was originally published in OTC Bulletin
Executive Summary
Sweden’s Moberg Pharma is to launch its Emtrix fungal nail product across the Middle East and Africa after signing an agreement with Mundipharma.
You may also be interested in...
Moberg Sells Consumer Health Portfolio To Pay For Rx Research Focus
Moberg had been expanding its OTC portfolio while also continuing trials for Rx ingredients including its MOB-015 formulation of terbinafine indicated for fingernail and toenail fungus. But $155m agreement with two investment groups will complete Moberg's divestment of consumer health brands.
Moberg Sells Consumer Health Portfolio To Pay For Focusing On Rx Research
Moberg had been expanding its OTC topical and nutritional supplement portfolio while also continuing trials for Rx ingredients including its MOB-015 formulation of terbinafine indicated for fingernail and toenail fungus. But $155m agreement with two investment groups will complete Moberg's divestment of consumer health brands and make it dedicated to R&D, regulatory matters and business development.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.